{
    "nctId": "NCT01075607",
    "briefTitle": "Lymph Fluid and Blood Collection for Identification of Novel Biomarkers",
    "officialTitle": "The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers",
    "overallStatus": "TERMINATED",
    "conditions": "Adenocarcinoma of the Breast",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Identification and Validation of Metastasis Protein Markers",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women, age greater than or equal to 18, with histologically and/or cytologically confirmed diagnosis of adenocarcinoma of the breast with metastatic (node positive) and/or non-metastatic (node negative) breast cancer.\n* No prior chemotherapy treatment.\n* Women, age greater than or equal to 18, with carcinoma in situ that opted for mastectomy.\n* Able to provide informed consent and HIPAA authorization.\n\nExclusion Criteria:\n\n* Hormone therapy in the past six months. Birth control pill use is allowed.\n* History of radiation therapy to the chest.\n* Previous or current use of aromatase inhibitor (AI) or Selective Estrogen Receptor Modulator (SERM) medication.\n* History of chemotherapy for breast or other cancers.\n* Pregnant or breast-feeding.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}